Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 2 Published - 14:00 UTC    08:00 EST    04-April-2001      
Issue 94 Next Update - 14:00 UTC 08:00 EST    05-April-2001      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya Today In Vidyyasm

Vidyya Medical News Service For 04-April-2001:

The following stories appear in full on Today's Vidyya Medical News Service Web site.

The eradication of crippling poliomyelitis is 99% complete according to figures released today by the Global Polio Eradication Initiative. In 2000, there were no more than 3500 cases of polio reported worldwide, a 99% decrease from the 350 000 annual cases estimated in 1988 when the Initiative was launched. In just 12 months the number of polio cases has been more than halved, from 7141 in 1999. This reduction is a result of the World Health Assembly’s call in 1999 to accelerate eradication activities, including increased rounds of National Immunization Days (NIDs) and use of a house-to-house vaccine delivery strategy enabling vaccination teams to find and immunize more children.

For more information: Polio Eradication: Final 1% Poses Greatest Challenge

Pfizer Inc. reported yesterday that newly published results of a clinical study showed that patients treated with Lipitor (atorvastatin calcium) upon hospital admission for an acute coronary syndrome (ACS) were significantly (59%) less likely to experience a non-fatal stroke within the following four months. New findings from the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) study were published in the 4 April 2001 issue of the Journal of the American Medical Association.

For more information: Results Of Lipitor® Trial Demonstrate Significant Reduction In Stroke For Certain Heart Patients

Lipitor (atorvastatin) is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, Apo B, and TG and to increase HDL-C levels in patients with primary hypercholesterolemia and mixed dyslipidemia. The recommended starting dose of atorvastatin is 10 mg once daily. The dosage range is 10 mg to 80 mg once daily. Atorvastatin is generally well tolerated. Get the full prescribing information in today's issue of Vidyya.

For more information: Prescribing Information: Lipitor (Artorvastatin ®)

For the first time ever, treatment guidelines used by oncology professionals to manage cancer pain have been translated into specific, reliable and easy-to-understand language for patients and their families. Today, the National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS) announced the availability of their first supportive care patient guidelines, Cancer Pain Treatment Guidelines for Patients.

For more information: American Cancer Society And National Comprehensive Cancer Network Develop New Pain Treatment Guidelines

About one-third of patients being treated for cancer have pain. More than two-thirds of patients with advanced cancer (cancer that has spread or recurred) have pain. For these patients, controlling pain and managing symptoms are important goals of treatment. Pain affects all aspects of quality of life. Patients who have chronic pain may not be able to participate in their regular activities as much, may have sleeping and eating problems, and may be frustrated that family and friends do not always understand how they feel. This patient guideline is designed to help patients discuss their pain with health professionals.

For more information: Cancer Pain Treatment Guidelines For Patients

Today's Vidyya articles are:

As always, we hope you enjoy the issue.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 
Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.